04:11 PM EDT, 04/22/2024 (MT Newswires) -- Vanda Pharmaceuticals' ( VNDA ) appeal to revive patent protections for its Hetlioz sleep-disorder medication was declined by the US Supreme Court, upholding a decision in favor of generic drugmakers Teva (TEVA) and Apotex, according to a ruling Monday.

A trial-level judge initially ruled the patents invalid in 2022 and that decision was upheld by the US Court of Appeals' federal circuit in August. Vanda petitioned the Supreme Court to review its case in January.

"While we are disappointed that the Supreme Court declined review of this case, we remain hopeful that the court will ultimately correct the governing standard," Vanda attorney Paul Hughes said, according to a Reuters report.

Teva said it was pleased with the Supreme Court's action, Reuters reported.

Vanda, Teva and Apotex did not immediately respond to MT Newswires' requests for comment.

Vanda shares fell 6.1% in regular trading Monday, and Teva gained 0.2%.